ATTD 2024 - Interview with Dr. Ohad Cohen Medtronic Diabetes

In this interview, host Rob interviews Dr. Ohad Cohen at ATTD 2024. They discuss the advancements in diabetes management technology, focusing on the MiniMed 780 g system and its impact on improving glycemic control and reducing the burden for people with type 1 diabetes. Dr. Cohen highlights the shift in focus towards achieving tighter glycemic targets and the integration of Simplera and new insulins with the 780 G system. The conversation also touches on the elimination of the label of "noncompliance" in diabetes management and the future of diabetes technology in reducing burden and improving outcomes.
00:00 Revolutionizing Diabetes Management with MiniMed 780G: A Breakthrough in Glycemic Control
03:25 Revolutionizing Diabetes Management with Technology: A Glance into the Future
Topics discussed:
Advancements in Diabetes Management Technology
Dr. Cohen expresses the need to go beyond current standards and embrace advancements like the MiniMed 780 g system.
Emphasis on achieving tighter glycemic control beyond the traditional range of 70 to 180.
Discussion on the improvement in glycemic control seen with the 780 g system and the potential for increased time spent in normal glycemic range.
Integration of Simplera and New Insulins
Dr. Cohen discusses the excitement around Simplera's integration with the 780 g system and the approval of new insulins like Novorapid, Fiasp, and Lyumjev.
The goal is to make diabetes management easier for individuals, removing barriers to achieving euglycemia.
Impact on Noncompliance and Diabetes Management Outcomes
Dr. Cohen reflects on the shift away from labeling individuals as noncompliant in diabetes management.
Results show that technology advancements like the 780 g system have helped individuals achieve better outcomes without the stigma of noncompliance.
The focus is on getting more people to better control without the fear of being labeled or stigmatized.
Future of Diabetes Technology
The future direction of diabetes technology is aimed at reducing the burden on individuals and improving outcomes.
Dr. Cohen highlights the importance of form factor, sensors, and algorithms in enhancing diabetes management.
The goal is to make diabetes management easier and more effective for a wider range of individuals, ultimately leading to better control and quality of life.
Key takeaways:
Advancements in diabetes technology, such as the MiniMed 780 g system, are revolutionizing diabetes management by focusing on tighter glycemic control and improved outcomes.
Integration of Simplera and new insulins with the 780 g system aims to make diabetes management more accessible and effective for individuals.
The elimination of the label of noncompliance in diabetes management signifies a shift towards empowering individuals to achieve better outcomes without stigma.
The future of diabetes technology is centered around reducing burden, improving control, and enhancing the quality of life for individuals with type 1 diabetes.
References:
MiniMed 780 G system
Simplera CGM from Medtronic
Novorapid, Fiasp, and Lyumjev insulins